Cosentyx (secukinumab) is a biologic medication used to treat autoimmune diseases such as psoriasis and psoriatic arthritis. Adjusting the dosage of Cosentyx can have an impact on its efficacy.

According to Drug Patent Watch [1], the recommended dose for Cosentyx is 300 mg administered subcutaneously at Weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks. However, the dosage can be adjusted based on the patient's response to treatment and the severity of their condition.

A study published in the Journal of Clinical and Aesthetic Dermatology [2] evaluated the efficacy of Cosentyx in treating moderate-to-severe plaque psoriasis. The study found that patients who received a higher dosage of Cosentyx (300 mg every 2 weeks) had a greater improvement in their psoriasis symptoms compared to those who received a lower dosage (300 mg every 4 weeks).

Another study published in the Journal of Dermatological Treatment [3] evaluated the efficacy of Cosentyx in treating psoriatic arthritis. The study found that patients who received a higher dosage of Cosentyx (300 mg every 2 weeks) had a greater improvement in their joint symptoms compared to those who received a lower dosage (300 mg every 4 weeks).

In conclusion, adjusting the dosage of Cosentyx can impact its efficacy in treating autoimmune diseases such as psoriasis and psoriatic arthritis. Patients should work closely with their healthcare provider to determine the appropriate dosage based on their response to treatment and the severity of their condition.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422944/
[3] https://pubmed.ncbi.nlm.nih.gov/35696305/